Search

Your search keyword '"Fujimoto, Daichi"' showing total 385 results
Start Over Author "Fujimoto, Daichi" Publication Type Academic Journals
385 results on '"Fujimoto, Daichi"'

5. Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning

Author

Fujimoto, Daichi, Shibaki, Ryota, Kimura, Keiichi, Haratani, Koji, Tamiya, Motohiro, Kijima, Takashi, Sato, Yuki, Hata, Akito, Yokoyama, Toshihide, Taniguchi, Yoshihiko, Uchida, Junji, Tanaka, Hisashi, Furuya, Naoki, Miura, Satoru, Onishi, Mihoko Imaji, Sakata, Shinya, Miyauchi, Eisaku, Yamamoto, Nobuyuki, Koh, Yasuhiro, and Akamatsu, Hiroaki

Published
2025
Full Text
View/download PDF

6. Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study

Author

Sugisaka, Jun, Fujimoto, Daichi, Tamiya, Motohiro, Hata, Akito, Matsumoto, Hirotaka, Yokoyama, Toshihide, Taniguchi, Yoshihiko, Uchida, Junji, Sato, Yuki, Kijima, Takashi, Tanaka, Hisashi, Furuya, Naoki, Masuda, Takeshi, Sakata, Yoshihiko, Miyauchi, Eisaku, Saito, Go, Miura, Satoru, Yamaguchi, Teppei, Daga, Haruko, Sakata, Shinya, Yamamoto, Nobuyuki, and Akamatsu, Hiroaki

Published
2025
Full Text
View/download PDF

8. Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial

Author

Shibaki, Ryota, Fujimoto, Daichi, Miyauchi, Eisaku, Tsukita, Yoko, Nakachi, Ichiro, Arai, Daisuke, Sakata, Yoshihiko, Shingu, Naoki, Shimokawa, Toshio, Kijima, Takashi, Tamiya, Motohiro, Kawana, Sachiko, Hara, Satoshi, Saito, Go, Sato, Yuki, Yokoyama, Toshihide, Sakata, Shinya, Taniguchi, Yoshihiko, Hata, Akito, Matsumoto, Hirotaka, Yamaguchi, Teppei, and Yamamoto, Nobuyuki

Published
2024
Full Text
View/download PDF

10. Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)

Author

Fujimoto, Daichi, Hayashi, Hidetoshi, Murotani, Kenta, Toi, Yukihiro, Yokoyama, Toshihide, Kato, Terufumi, Yamaguchi, Teppei, Tanaka, Kaoru, Miura, Satoru, Tamiya, Motohiro, Tachihara, Motoko, Shukuya, Takehito, Tsuchiya-Kawano, Yuko, Sato, Yuki, Ikeda, Satoshi, Sakata, Shinya, Masuda, Takeshi, Takemoto, Shinnosuke, Otsubo, Kohei, Shibaki, Ryota, Makino, Miki, Okamoto, Isamu, and Yamamoto, Nobuyuki

Published
2024
Full Text
View/download PDF

13. Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer

Author

Fujimoto, Daichi, Miura, Satoru, Tomii, Keisuke, Sumikawa, Hiromitsu, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Yokoyama, Toshihide, Kijima, Takashi, Asao, Tetsuhiko, Tamiya, Motohiro, Nakamura, Atsushi, Yoshioka, Hiroshige, Tokito, Takaaki, Murakami, Shuji, Tamiya, Akihiro, Yokouchi, Hiroshi, Watanabe, Satoshi, Yamaguchi, Ou, Morinaga, Ryotaro, Jodai, Takayuki, Ito, Kentaro, Shiraishi, Yoshimasa, Kogure, Yoshihito, Shibaki, Ryota, and Yamamoto, Nobuyuki

Published
2023
Full Text
View/download PDF

15. Prediction of the debulking effect of rotational atherectomy using optical frequency domain imaging: a prospective study

Author

Hamana, Tomoyo, Kawamori, Hiroyuki, Toba, Takayoshi, Nishimori, Makoto, Tanimura, Kosuke, Kakizaki, Shunsuke, Nakamura, Koichi, Fujimoto, Daichi, Sasaki, Satoru, Osumi, Yuto, Fujii, Masayoshi, Iwane, Seigo, Yamamoto, Tetsuya, Naniwa, Shota, Sakamoto, Yuki, Fukuishi, Yuta, Matsuhama, Koshi, Hirata, Ken-ichi, and Otake, Hiromasa

Published
2023
Full Text
View/download PDF

16. Clinical impact of optical coherence tomography findings after drug-coated balloon treatment for patients with acute coronary syndromes

Author

Yamamoto, Tetsuya, Kawamori, Hiroyuki, Toba, Takayoshi, Kakizaki, Shunsuke, Nakamura, Koichi, Fujimoto, Daichi, Sasaki, Satoru, Fujii, Hiroyuki, Hamana, Tomoyo, Osumi, Yuto, Iwane, Seigo, Naniwa, Shota, Sakamoto, Yuki, Matsuhama, Koshi, Fukuishi, Yuta, Kozuki, Amane, Shite, Junya, Iwasaki, Masamichi, Ishida, Akihiko, Hirata, Ken-ichi, and Otake, Hiromasa

Published
2023
Full Text
View/download PDF

19. Real-world clinical outcomes of percutaneous transluminal septal myocardial ablation for patients with drug-refractory hypertrophic obstructive cardiomyopathy: results from a retrospective multicenter registry of non-high-volume centers

Author

Nakamura, Koichi, Toba, Takayoshi, Otake, Hiromasa, Kakizaki, Shunsuke, Fujimoto, Daichi, Takahashi, Yu, Fukuyama, Yusuke, Kawamori, Hiroyuki, Tanaka, Hidekazu, Takaya, Tomofumi, Iwasaki, Masamichi, Kozuki, Amane, Kawai, Hiroya, Hayashi, Takatoshi, Shite, Junya, and Hirata, Ken-ichi

Published
2022
Full Text
View/download PDF

24. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

Author

Takeda, Masayuki, Shimokawa, Mototsugu, Nakamura, Atsushi, Nosaki, Kaname, Watanabe, Yasutaka, Kato, Terufumi, Hayakawa, Daisuke, Tanaka, Hiroshi, Takahashi, Toshiaki, Oki, Masahide, Tachihara, Motoko, Fujimoto, Daichi, Hayashi, Hidetoshi, Yamaguchi, Kakuhiro, Yamamoto, Shoichiro, Iwama, Eiji, Azuma, Koichi, Hasegawa, Kazuo, Yamamoto, Nobuyuki, and Nakagawa, Kazuhiko

Published
2023
Full Text
View/download PDF

25. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study

Author

Imaji, Mihoko, Fujimoto, Daichi, Sato, Yuki, Sakata, Yoshihiko, Oya, Yuko, Tamiya, Motohiro, Suzuki, Hidekazu, Ikeda, Hideki, Kijima, Takashi, Matsumoto, Hirotaka, Kanazu, Masaki, Hino, Aoi, Inaba, Megumi, Tsukita, Yoko, Arai, Daisuke, Maruyama, Hirotaka, Hara, Satoshi, Tsumura, Shinsuke, Kobe, Hiroshi, Sumikawa, Hiromitsu, Sakata, Shinya, and Yamamoto, Nobuyuki

Published
2023
Full Text
View/download PDF

26. Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

Author

Terai, Hideki, Soejima, Kenzo, Shimokawa, Asanao, Horinouchi, Hidehito, Shimizu, Junichi, Hase, Tetsunari, Kanemaru, Ryota, Watanabe, Kana, Ninomiya, Kiichiro, Aragane, Naoko, Yanagitani, Noriko, Sakata, Yoshihiko, Seike, Masahiro, Fujimoto, Daichi, Kasajima, Masashi, Kubo, Akihito, Kusumoto, Sojiro, Oyamada, Yoshitaka, Fujiwara, Keiichi, Mori, Masahide, Hashimoto, Midori, Shingyoji, Masato, Kodani, Masahiro, Sakamoto, Jin, Agatsuma, Toshihiko, Kashiwabara, Kosuke, Inomata, Minehiko, Tachihara, Motoko, Tanaka, Kazuhisa, Hayashihara, Kenji, Koyama, Nobuyuki, Matsui, Kaoru, Minato, Koichi, Jingu, Daisuke, Sakashita, Hiroyuki, Hara, Satoshi, Naito, Tomoyuki, Okada, Asuka, Tanahashi, Masayuki, Sato, Yuki, Asano, Koichiro, Takeda, Takayuki, Nakazawa, Kensuke, Harada, Toshiyuki, Shibata, Kazuhiko, Kato, Tatsuo, Miyaoka, Etsuo, Yoshino, Ichiro, Gemma, Akihiko, and Mitsudomi, Tetsuya

Published
2022
Full Text
View/download PDF

28. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting

Author

Sato, Yuki, Sumikawa, Hiromitsu, Shibaki, Ryota, Morimoto, Takeshi, Sakata, Yoshihiko, Oya, Yuko, Tamiya, Motohiro, Suzuki, Hidekazu, Matsumoto, Hirotaka, Yokoi, Takashi, Hashimoto, Kazuki, Kobe, Hiroshi, Hino, Aoi, Inaba, Megumi, Tsukita, Yoko, Ikeda, Hideki, Arai, Daisuke, Maruyama, Hirotaka, Hara, Satoshi, Tsumura, Shinsuke, Sakata, Shinya, and Fujimoto, Daichi

Published
2022
Full Text
View/download PDF

30. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study

Author

Kenmotsu, Hirotsugu, Wakuda, Kazushige, Mori, Keita, Kato, Terufumi, Sugawara, Shunichi, Kirita, Keisuke, Yoneshima, Yasuto, Azuma, Koichi, Nishino, Kazumi, Teraoka, Shunsuke, Shukuya, Takehito, Masuda, Ken, Hayashi, Hidetoshi, Toyozawa, Ryo, Miura, Satoru, Fujimoto, Daichi, Nakagawa, Kazuhiko, Yamamoto, Nobuyuki, and Takahashi, Toshiaki

Published
2022
Full Text
View/download PDF

32. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Author

Hayashi, Hidetoshi, Yonesaka, Kimio, Nakamura, Atsushi, Fujimoto, Daichi, Azuma, Koichi, Sakata, Shinya, Tachihara, Motoko, Ikeda, Satoshi, Yokoyama, Toshihide, Hataji, Osamu, Yano, Yukihiro, Hirano, Katsuya, Daga, Haruko, Okada, Hideaki, Chiba, Yasutaka, Sakai, Kazuko, Nishio, Kazuto, Yamamoto, Nobuyuki, and Nakagawa, Kazuhiko

Published
2022
Full Text
View/download PDF

34. Thermally Stable Heteroleptic Trans‐Bis(Chelate) Ruthenium(II) Complex Bearing 2,2'‐Bipyridine and Acetylacetonato: Synthesis, Isomerization, and Crystal Structure.

Author

Toyama, Mari, Fujimoto, Daichi, Kawakami, Yusuke, and Tanaka, Shiho

Subjects
*STERIC hindrance, *LIGANDS (Chemistry), *X-ray crystallography, *NUCLEAR magnetic resonance spectroscopy, *DIHEDRAL angles
Abstract

Thermally stable trans‐bis(chelate)‐type Ru(II) complexes are challenging to prepare owing to steric hindrance between the two chelate ligands. Herein, we investigated the isomerization of a heteroleptic cis‐bis(chelate) complex to obtain its trans form. cis‐[Ru(acac)(bpy)(dmso‐S)2](OTf)⋅0.5H2O (1⋅(OTf)⋅0.5H2O; acac−=acetylacetonato; bpy=2,2'‐bipyridine; dmso=dimethyl sulfoxide; OTf−=CF3SO3−) was prepared by reacting trans(O,S)‐[Ru(bpy)(dmso‐S)2(dmso‐O)2](OTf)2 (P0) with Li(acac) in acetone at 298 K. In 1⋅(OTf)⋅0.5H2O, the two labile dmso‐O ligands of P0 were replaced by an acac− ligand. The dihedral angle between the chelate rings of bpy and acac− in 1+ was 76.7°, suggesting steric hindrance between ligands owing to the two bulky dmso‐S ligands at the cis position. 1⋅(OTf)⋅0.5H2O was thermally stable in DMSO and acetone; however, in methanol and water, a dmso‐S ligand was dissociated from 1+, and the complex isomerized to trans‐[Ru(acac)(bpy)(dmso‐S)(solvent)]+. Refluxing of 1⋅(OTf)⋅0.5H2O in methanol for 18 h, evaporation to dryness under vacuum, and treatment with water yielded trans‐[Ru(acac)(bpy)(dmso‐S)(OH2)](OTf) (2⋅(OTf)) with excellent purity. 2⋅(OTf) was characterized by X‐ray crystallography, elemental analysis, and 1H NMR spectroscopy. As expected, steric hindrance was not observed between the trans‐arranged bpy and acac−, and the two chelates laid flat on the equatorial plane in 2+. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Differences in total plaque burden between plaque rupture and plaque erosion: A combined computed tomography angiography and optical coherence tomography study.

Author

Niida, Takayuki, Usui, Eisuke, Suzuki, Keishi, Kinoshita, Daisuke, Yuki, Haruhito, Fujimoto, Daichi, Covani, Marco, Dey, Damini, Lee, Hang, McNulty, Iris, Ferencik, Maros, Yonetsu, Taishi, Kakuta, Tsunekazu, and Jang, Ik-Kyung

Abstract

Coronary computed tomography angiography (CTA) allows for the assessment of atherosclerotic plaque burden across the entire coronary vasculature. No studies have examined the relationship between the underlying pathology of the culprit lesion and total plaque burden in patients with acute coronary syndromes. The aim of this study was to compare the total plaque burden between patients with plaque rupture versus plaque erosion. A total of 232 patients who presented with their first non-ST-segment elevation acute coronary syndrome and underwent both CTA and optical coherence tomography imaging before intervention were selected. Quantitative analysis was performed using semi-automated software (Autoplaque version 3.0, Cedars-Sinai Medical Center). An attenuation of <30 Hounsfield units defined low-density non-calcified plaque (LDNCP). All 3 vessels were assessed using the modified 17-segment American Heart Association model for coronary segment classification. Among 232 patients, 125 (53.9%) had plaque rupture and 107 (46.1%) had plaque erosion. Total plaque burden (48.2 [39.8–54.9] % vs. 44.1 [38.6–50.0] %, P ​= ​0.006), total non-calcified plaque (NCP) burden (46.6 [39.1–53.3] % vs. 43.0 [37.6–49.2] %, P ​= ​0.013), total LDNCP burden (2.3 [1.4–3.0] % vs. 1.7 [1.2–2.6] %, P ​= ​0.016), and total calcified plaque (CP) burden (0.8 [0.1–1.6] % vs. 0.4 [0.0–1.4] %, P ​= ​0.047) were significantly greater in patients with culprit plaque rupture than in those with culprit plaque erosion. Patients with plaque rupture, compared with those with plaque erosion, had a greater total plaque burden, NCP burden, LDNCP burden, and CP burden. URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04523194. Patients with plaque rupture had a greater total plaque burden than those with plaque erosion. LAD ​= ​left anterior descending artery; LCX ​= ​left circumflex artery; RCA ​= ​right coronary artery. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Relationship between plaque burden and plaque vulnerability: Acute coronary syndromes versus chronic coronary syndrome.

Author

Kinoshita, Daisuke, Suzuki, Keishi, Fujimoto, Daichi, Niida, Takayuki, Usui, Eisuke, Minami, Yoshiyasu, Dey, Damini, Lee, Hang, McNulty, Iris, Ako, Junya, Ferencik, Maros, Kakuta, Tsunekazu, and Jang, Ik-Kyung

Abstract

The relationship between plaque burden and microscopic characterization of plaque features as it pertains to clinical presentation has not been fully investigated. The aim of this study was to compare the relationship between plaque burden and plaque vulnerability in patients with acute coronary syndromes (ACS) versus chronic coronary syndrome (CCS). Patients who underwent both coronary computed tomography angiography (CTA) and optical coherence tomography (OCT) before coronary intervention were enrolled. All plaques were detected in culprit vessels using CTA, and total plaque volume (TPV) and OCT features were assessed at the corresponding sites. All plaques were divided into three groups according to the tertile levels of TPV (low TPV: <96.5 ​mm3, moderate TPV: 96.5–164.7 ​mm3, high TPV: ≥164.8 ​mm3). A total of 990 plaques were imaged by OCT in 419 patients: 445 plaques in 190 (45.3%) patients with ACS and 545 in 229 (54.7%) with CCS. Macrophage was more prevalent in plaques with greater TPV in patients who presented with ACS but not in those who presented with CCS (low vs. moderate vs. high TPV group: macrophage 57.4% vs. 71.8% vs. 82.4% in ACS; 63.4% vs. 67.8% vs. 66.7% in CCS; interaction P ​= ​0.004). Lipid arc increased as TPV increased, especially in patients who presented with ACS. Conversely, the layer index increased as TPV increased in patients with CCS. Greater plaque burden was closely related to higher levels of plaque vulnerability in ACS and greater volume of layered plaque in CCS. clinicaltrials.gov Identifier: NCT04523194. Plaque burden has been demonstrated to be associated with plaque vulnerability. The relationship between plaque burden and vulnerability could differ between acute coronary syndromes (ACS) and chronic coronary syndrome (CCS). However, no study systematically compared the relationship. This study demonstrated that as total plaque volume increased, the levels of plaque vulnerability increased in ACS, whereas microscopic features related to the plaque healing process, such as calcification and layered plaque formation, became more prevalent in CCS. The results suggest that patients presenting with either ACS or CCS may require distinct management strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Cholesterol uptake capacity: A new measure of high-density lipoprotein functionality as a predictor of subsequent revascularization in patients undergoing percutaneous coronary intervention

Author

Fujimoto, Daichi, Otake, Hiromasa, Kawamori, Hiroyuki, Toba, Takayoshi, Nagao, Manabu, Nakano, Shinsuke, Tanimura, Kosuke, Takahashi, Yu, Fukuyama, Yusuke, Kakizaki, Shunsuke, Nakamura, Koichi, Harada, Amane, Murakami, Katsuhiro, Iino, Takuya, Toh, Ryuji, and Hirata, Ken-ichi

Published
2022
Full Text
View/download PDF

38. A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

Author

Fujimoto, Daichi, Miura, Satoru, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Haratani, Koji, Itoh, Shoichi, Uemura, Takehiro, Morinaga, Ryotaro, Takahama, Takayuki, Nakashima, Kazuhisa, Tachihara, Motoko, Saito, Go, Tanizaki, Junko, Otsubo, Kohei, Ikeda, Satoshi, Matsumoto, Hirotaka, Hara, Satoshi, Hata, Akito, Masuda, Takeshi, and Yamamoto, Nobuyuki

Published
2022
Full Text
View/download PDF

39. Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002

Author

Tamiya, Motohiro, Fujikawa, Kei, Suzuki, Hidekazu, Yokoyama, Toshihide, Uenami, Takeshi, Tamiya, Akihiro, Sato, Yuki, Saito, Go, Uchida, Junji, Morita, Mitsunori, Hirashima, Tomonori, Fukuda, Yasushi, Kanazu, Masaki, Hosoya, Kazutaka, Suzuki, Takuji, Ueno, Kiyonobu, Fujimoto, Daichi, Kumagai, Toru, and Teramukai, Satoshi

Published
2022
Full Text
View/download PDF

43. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study

Author

Fujimoto, Daichi, Miura, Satoru, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Yokoyama, Toshihide, Yokoi, Takashi, Asao, Tetsuhiko, Tamiya, Motohiro, Nakamura, Atsushi, Yoshioka, Hiroshige, Haratani, Koji, Teraoka, Shunsuke, Tokito, Takaaki, Murakami, Shuji, Tamiya, Akihiro, Itoh, Shoichi, Yokouchi, Hiroshi, Watanabe, Satoshi, Yamaguchi, Ou, Tomii, Keisuke, and Yamamoto, Nobuyuki

Published
2021
Full Text
View/download PDF

44. Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study

Author

Ito, Kentaro, Yamanaka, Takeharu, Hayashi, Hidetoshi, Hattori, Yoshihiro, Nishino, Kazumi, Kobayashi, Haruki, Oya, Yuko, Yokoyama, Toshihide, Seto, Takashi, Azuma, Koichi, Fukui, Tomoya, Kozuki, Toshiyuki, Nakamura, Atsushi, Tanaka, Kentaro, Hirano, Katsuya, Yokoi, Takashi, Daga, Haruko, Sakata, Shinya, Fujimoto, Daichi, Mori, Masahide, Maeno, Ken, Aoki, Takuya, Tamura, Atsuhisa, Miura, Satoru, Watanabe, Satoshi, Akamatsu, Hiroaki, Hataji, Osamu, Suzuki, Kensuke, Hontsu, Shigeto, Azuma, Koji, Bessho, Akihiro, Kubo, Akihito, Okuno, Motoyasu, Nakagawa, Kazuhiko, and Yamamoto, Nobuyuki

Published
2021
Full Text
View/download PDF

46. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Author

Hosoya, Kazutaka, Fujimoto, Daichi, Morimoto, Takeshi, Kumagai, Toru, Tamiya, Akihiro, Taniguchi, Yoshihiko, Yokoyama, Toshihide, Ishida, Tadashi, Hirano, Katsuya, Matsumoto, Hirotaka, Kominami, Ryota, Tomii, Keisuke, Suzuki, Hidekazu, Hirashima, Tomonori, Uchida, Junji, Morita, Mitsunori, Kanazu, Masaki, Sawa, Nobuhiko, Makio, Takeshi, Hara, Satoshi, and Tamiya, Motohiro

Published
2020
Full Text
View/download PDF

47. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan

Author

Morita, Ryo, Okishio, Kyoichi, Shimizu, Junichi, Saito, Haruhiro, Sakai, Hiroshi, Kim, Young Hak, Hataji, Osamu, Yomota, Makiko, Nishio, Makoto, Aoe, Keisuke, Kanai, Osamu, Kumagai, Toru, Kibata, Kayoko, Tsukamoto, Hiroaki, Oizumi, Satoshi, Fujimoto, Daichi, Tanaka, Hiroshi, Mizuno, Keiko, Masuda, Takeshi, Kozuki, Toshiyuki, Haku, Takashi, Suzuki, Hiroyuki, Okamoto, Isamu, Hoshiyama, Hirotoshi, Ueda, Junya, and Ohe, Yuichiro

Published
2020
Full Text
View/download PDF

48. Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)

Author

Okishio, Kyoichi, Morita, Ryo, Shimizu, Junichi, Saito, Haruhiro, Sakai, Hiroshi, Kim, YoungHak, Hataji, Osamu, Yomota, Makiko, Nishio, Makoto, Aoe, Keisuke, Kanai, Osamu, Kumagai, Toru, Kibata, Kayoko, Tsukamoto, Hiroaki, Oizumi, Satoshi, Fujimoto, Daichi, Tanaka, Hiroshi, Mizuno, Keiko, Masuda, Takeshi, Kozuki, Toshiyuki, Haku, Takashi, Suzuki, Hiroyuki, Okamoto, Isamu, Hoshiyama, Hirotoshi, Yada, Nobumichi, and Ohe, Yuichiro

Published
2020
Full Text
View/download PDF

49. “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy

Author

Torlakovic, Emina, Lim, Hyun J., Adam, Julien, Barnes, Penny, Bigras, Gilbert, Chan, Anthony W.H., Cheung, Carol C., Chung, Jin-Haeng, Couture, Christian, Fiset, Pierre O., Fujimoto, Daichi, Han, Gang, Hirsch, Fred R., Ilie, Marius, Ionescu, Diana, Li, Chao, Munari, Enrico, Okuda, Katsuhiro, Ratcliffe, Marianne J., Rimm, David L., Ross, Catherine, Røge, Rasmus, Scheel, Andreas H., Soo, Ross A., Swanson, Paul E., Tretiakova, Maria, To, Ka F., Vainer, Gilad W., Wang, Hangjun, Xu, Zhaolin, Zielinski, Dirk, and Tsao, Ming-Sound

Published
2020
Full Text
View/download PDF

50. The association of intraoperative end-tidal carbon dioxide with the risk of postoperative nausea and vomiting

Author

Fujimoto, Daichi, Egi, Moritoki, Makino, Shohei, and Mizobuchi, Satoshi

Subjects
Medical research, Medicine, Experimental, Droperidol, Carbon dioxide, Health
Abstract

Purpose Patients undergoing gynecological surgery are considered to be a high-risk cohort for postoperative nausea and vomiting (PONV). The purpose of this study was to assess the association of intraoperative end-tidal carbon dioxide (EtCO.sub.2) with risk of PONV in patients underwent gynecological open surgery. Methods In this single-center retrospective observational study, we included patients aged 20-60 years who underwent elective gynecological open surgery. We obtained data for the incidence of PONV within 24 h after operation. We collected EtCO.sub.2 every minute during the operation, and determined the lowest value of EtCO.sub.2. We compared the lowest EtCO.sub.2 between patients with and without PONV. Multivariate logistic regression analysis was performed to assess the independent association of EtCO.sub.2 with the risk of PONV. Results A total of 146 patients were included in the current study. There were 81 patients with PONV within 24 h after the operation. The median lowest value of EtCO.sub.2 in patients with PONV was significantly lower than that in patients without PONV (31 vs 33 mmHg, p = 0.02). In the multivariate logistic regression model, we found that lowest EtCO.sub.2 [less than or equal to] 31 mmHg was independently associated with increase in the risk of PONV (adjusted odds ratio = 3.37, p = 0.02). Conclusion In this retrospective observational study, low intraoperative EtCO.sub.2 was shown to be independently associated with increased risk of PONV. However, this result may be skewed by uncollected information including previous PONV, motion sickness or other unknown bias, so future studies should be conducted to refute or confirm our findings., Author(s): Daichi Fujimoto [sup.1], Moritoki Egi [sup.1], Shohei Makino [sup.1], Satoshi Mizobuchi [sup.1] Author Affiliations: (1) grid.411102.7, 0000 0004 0596 6533, Department of Anesthesiology, Kobe University Hospital, , 7-5-2 Kusunoki-cho, [...]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results